[CAS NO. 14484-47-0] Deflazacort

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [14484-47-0]

Catalog

AS965474

Brand

Arctom Scientific

CAS

14484-47-0

DESCRIPTION [14484-47-0]

Overview

MDL	-
Molecular Weight	441.52
Molecular Formula	C25H31NO6
SMILES	O=C1C=C[C@@]2(C)C(CC[C@]3([H])[C@]2([H])[C@@H](O)C[C@@]4(C)[C@@]3([H])C[C@]5([H])[C@@]4(C(COC(C)=O)=O)N=C(C)O5)=C1

For research use only. We do not sell to patients.

Summary

Deflazacort, a glucocorticoid, is an inactive prodrug and is converted rapidly to the active metabolite 21-desacetyldeflazacort. Deflazacort is used as an anti-inflammatory and immunosuppressant ^[1] .

In Vitro

Deflazacort is an inactive prodrug which is converted rapidly to the active metabolite 21-desacetyldeflazacort. Maximum concentrations of 21-desacetyldeflazacort averaged 116 ng/ml and were observed after 1.3 h. The average area under the curve was 280 ng/ml.h, and the terminal half-life was 1.3 h. 21-Desacetyldeflazacort was cleared significantly faster than both methylprednisolone and prednisolone ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT04365088	Yuzuncu Y?l University	Impacted Third Molar Tooth	December 15, 2018	Phase 4
NCT04543370	Catabasis Pharmaceuticals	Healthy	August 8, 2020	Phase 1
NCT03783923	PTC Therapeutics	Limb-Girdle Muscular Dystrophy	October 31, 2019	Phase 3
NCT01603407	University of Rochester\|Newcastle University\|University Medical Center Freiburg\|National Institute of Neurological Disorders and Stroke (NINDS)	Duchenne Muscular Dystrophy	January 2013	Phase 3
NCT00527228	Ludwig-Maximilians - University of Munich	LGMD2B\|Miyoshi Myopathy\|Dysferlinopathy	September 2003	Phase 2\|Phase 3
NCT04227483	Postgraduate Institute of Medical Education and Research	Allergic Bronchopulmonary Aspergillosis	January 15, 2020	Phase 2\|Phase 3
NCT04791345	Parc de Salut Mar	Healthy Volunteers	February 26, 2021	Phase 1
NCT02251600	PTC Therapeutics	Duchenne Muscular Dystrophy	December 2014	Phase 1
NCT02286635	PTC Therapeutics	Healthy Volunteers	November 2014	Phase 1
NCT02485431	PTC Therapeutics\|ICON Development Solutions	Healthy Volunteers	June 2015	Phase 1
NCT02295748	PTC Therapeutics	Duchenne Muscular Dystrophy	December 2014	Phase 1
NCT02286622	PTC Therapeutics	Renal Impairment	December 2014	Phase 1
NCT04740554	University of Sao Paulo	Duchenne Muscular Dystrophy	March 1, 2013
NCT01817322	Samsung Medical Center	Chronic Renal Disease	June 2011	Phase 4
NCT03642145	PTC Therapeutics	Duchenne Muscular Dystrophy	October 31, 2018	Phase 3
NCT02286609	PTC Therapeutics	Hepatic Impairment	December 2014	Phase 1
NCT02592941	PTC Therapeutics\|Parexel\|Dohmen Life Science Services	Duchenne Muscular Dystrophy

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL ( 226.49 mM )

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.2649 mL	11.3245 mL	22.6490 mL
5 mM	0.4530 mL	2.2649 mL	4.5298 mL
10 mM	0.2265 mL	1.1325 mL	2.2649 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (5.66 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (5.66 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (5.66 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Mollmann, H., et al., Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone. Pharmaceutical research, 1995. 12(7): p. 1096-1100.

Synonyms

5′H-Pregna-1,4-dieno[17,16-d]oxazole-3,20-dione, 21-(acetyloxy)-11-hydroxy-2′-methyl-, (11β,16β)-

5′βH-Pregna-1,4-dieno[17,16-d]oxazole-3,20-dione, 11β,21-dihydroxy-2′-methyl-, 21-acetate

2H-Naphth[2′,1′:4,5]indeno[1,2-d]oxazole, 5′H-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione deriv.

(11β,16β)-21-(Acetyloxy)-11-hydroxy-2′-methyl-5′H-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione

Deflazacort

Dezacort

Flantadin

Azacort

DL 458IT

L 5458

Lantadin

MDL 458

Deflan

Dezacor

Calcort

Oxazacort

Azacortinol

Emflaza